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Abstract 
This report describes the diagnostic features, clinical management and the issues 
associated with management of a young immunocompetent male who presented with a 
presumed left Herpes simplex immune stromal keratitis, and ten months later, a right 
immune stromal keratitis associated with Herpes zoster ophthalmicus.  
 
Clinical case 
A 35 year old Caucasian male presented to Vision Eye Institute with a history of left 
epiphora, photophobia and blur. Symptoms had been present for approximately two 
weeks. His past ocular history was significant for a right corneal alkali-based chemical 
burn due to hair dye, sustained nine years previous, which had required hospital-based 
intensive topical therapeutic management for one week. Following this incident, the 
vision in the right eye had been somewhat impaired. His general health history was 
unremarkable. There was no previous history of herpetic corneal disease. 
On examination, Visual Acuity was R 6/12 and L 6/9. Slit lamp examination revealed a 
band of right inferior vascularization from 5 o’clock to 9 o’clock and a clear central 
cornea (Figure 1).  A left diffuse, vascularized, anterior stromal keratitis was evident 
(Figures 2A and 2B). There was no associated anterior uveitis. Both corneas were 
negative for vital staining with sodium fluorescein and rose Bengal. Of clinical 
significance was the reduction in left central corneal sensation relative to the right eye 
as measured with a 0.12 mm nylon monofilament (Cochet-Bonnet aesthesiometer, 
Luneau Ophthalmlogie, Chartres, France): R 6 cm L 4.5 cm (normal value 
5.5 ± 0.8 cm).1 IOP was R 10 L 9 mmHg (Applanation Tonometer, model HA-2, Kowa). 
External examination revealed a moderate bilateral anterior Staphylococcal blepharitis. 
A fluid-filled vesicle was noted on the left upper mucocutaneous junction of the lip. A 
polymerase chain reaction (PCR) swab of the left conjunctival fornix was negative for 
herpes viruses, adenovirus and Chlamydia. A left forniceal bacterial swab was also 
negative. PCR of the facial vesicle was positive for Herpes simplex virus-1 (HSV-1.)  
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Left  immune stromal keratitis (ISK) presumed due to HSV-1 was diagnosed and the 
patient was prescribed a slowly tapering course of prednisolone acetate 1% (Prednefrin 
forte, Allergan, Irvine, USA) commencing at two hourly dosing and topical acyclovir 3% 
ointment (Zovirax Ophthamic Ointment, GlaxoSmithKline, Middlesex, UK) commencing 
at thrice daily. Concomitant use of eyelid hygiene procedures twice daily and 
preservative-free artificial tears (Blink Intensive, Abbott, Illinois, USA) four times daily 
was prescribed. The outdoors wearing of 100% UV protection sunglasses and a hat 
were advised.  
Symptoms and signs in the left eye gradually improved over 3/12 with VA of 6/6 
achieved. The topical steroid and antiviral were discontinued and the patient was 
advised to continue UV protective measures, lid hygiene procedures and non-
preserved artificial tears. At review three months following cessation of the topical 
steroid and antiviral, left VA was 6/6 and a mild residual anterior stromal scar with 
diminished filling of the corneal vessels was evident (Figure 2C). 
At ten months after the initial presentation, the patient presented via general 
practitioner referral with presumed right herpes zoster ophthalmicus (HZO) following a 
three day prodromal of right-sided scalp, forehead and periocular pain followed by the 
eruption of a painful right-sided oedematous, vesicular rash. A PCR swab of a forehead 
vesicle was positive for Varicella zoster virus (VZV).  
The rash had started on the scalp and migrated down the forehead to the periocular 
area and been present for one week (Figure 3). Oral valacyclovir 1000 mg (Valtrex, 
GlaxoSmithKline, Middlesex, UK) thrice daily had been commenced approximately 48 
hours after the rash appeared. VA was R 6/15 L 6/6. A right diffuse patchy anterior 
stromal ISK was present (Figures 4a and 4b). The left corneal appearance was 
unchanged. There was no associated anterior uveitis. Both corneas were negative for 
vital staining with sodium fluorescein and rose Bengal. IOP was R 14 L 14 mmHg. The 
patient advised to continue his 7 day course of oral valacyclovir and was commenced 
on prednisolone acetate 1% qid RE. He was advised to continue bilateral lid hygiene 
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procedures and non-preserved artificial tears. Pregabalin (Lyria, Pfizer, New York, 
USA) 150mg per day for two months was prescribed by his general practitioner for 
zoster related neuropathic pain. 
The right stromal haze gradually resolved over the following three months and the 
prednisolone acetate was gradually tapered and withdrawn. VA was R 6/12 L 6/6. 
Corneal aesthesiometry was R 3.0 cm L 3.5 cm. Artificial tears and lid hygiene were 
continued. 
Following discussion with the patient’s general practitioner, and given the recent history 
of bilateral herpetic corneal disease, the patient was commenced on a prophylactic 12 
month course of oral valacyclovir 500mg daily. 
 
Discussion 
The presentation of a bilateral consecutive immune stromal keratitis without epithelial 
involvement due to Herpes simplex in one eye and then HZO in the other eye in an 
immunocompetent 35-year-old is atypical and an extensive review of the literature 
revealed that a similar case has not been reported. Herpetic corneal disease typically 
manifests as a dendritic epithelial ulcerative keratitis in Herpes simplex2 and a punctate 
epitheliopathy or infiltrative dendritic epithelial keratitis in HZO.3,4 The incidence of new 
and recurrent epithelial keratitis in the USA has been estimated at 15.6 per 100,000 
person years, and for stromal keratitis this incidence is considerably lower at 2.6 per 
100,000 person years.2 The incidence of Herpes zoster keratitis is 8.8 per 100,000 
person years.5 Epithelial keratitis has been reported in 51-60% of individuals with HZO 
and stromal keratitis occurs somewhat less frequently in 40-54%.3,4 Whilst herpes 
simplex keratitis can occur at any age, HZO occurs more frequently in the elderly and 
in the immunocompromised. A recent review of confirmed HZO cases determined only 
13% (8/134) occurred in the 25-44 year age group.5  
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Immune stromal keratitis (ISK), also known as interstitial keratitis, is a non-ulcerative 
inflammatory reaction of the corneal stroma occurring as a result of a CD4+ immune-
mediated host response.6,7 It may present as small, white stromal opacities (as per this 
patient’s right eye presentation) or as a dense white cellular infiltrate (as per the left 
eye). An accompanying immune ring may be present. The chronic and recurrent nature 
of this response can lead within days or weeks to corneal stromal oedema, 
neovascularisation, thinning and scarring (as per the left eye).  
The inflammation can occur at any level or location on the cornea.7 Fortunately, in our 
patient the involvement was restricted to the anterior stroma and was not accompanied 
by endothelitis, trabecultiis or iridocyclitis.8 Nor was the patient a steroid responder and 
hence the complications of elevated IOP associated with the steroid based 
management of ISK were not encountered.  
In a case series review of the aetiology of ISK, Herpes simplex virus (HSV) accounted 
for the majority (71.4%) of unilateral active ISK cases and varicella-zoster virus for 
8.6%.7 In the same ISK case series, 14.3% of cases were classified as idiopathic 
following medical work up and laboratory assessments. Whilst PCR assessment of the 
tear fluid in clinically active HSV is positive in approximately 81% of active epithelial 
keratitis cases, it is only positive in approximately 59% of active stromal keratitis 
cases.9 It remains possible, although not probable, that the left stromal keratitis, 
presumed herpetic due to reduced corneal sensation and PCR HSV1 concurrent 
positive facial lesion but not confirmed by PCR of tear fluid in the conjunctival sac, was 
indeed a stromal Staphlyococcal hypersensitivity reaction associated with the co-
existent Staphylococcal blepharitis. 
Stromal keratitis associated with Herpes simplex and Herpes zoster is a leading cause 
of corneal opacification and corneal blindness in the developed world, and an important 
indication for penetrating keratoplasty.2,7,10 Hence issues surrounding timely diagnosis, 
ongoing therapeutic management, regular review and implementing strategies aimed at 
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preventing and/or managing recurrences are of importance to maintaining life-long 
vision. 
HSV 1 keratitis is usually diagnosed by a recurrent characteristic clinical course 
involving dendritic epithelial lesions and possible associated facial blisters. However, 
HSV-1 can infect the underlying corneal stroma and cause herpetic stromal keratitis.11 
Stromal keratitis may involve active viral replication within the stroma with an overlying 
epithelial defect and high risk of stromal melting and perforation (necrotizing keratitis) 
but more commonly, as in this case, it occurs as a result an immune-mediated host 
response.11 Neurotrophic keratitis and perforation can occur, particularly in chronic or 
recurrent cases.11  
HZO is typically diagnosed by a characteristic and usually painful zoster rash involving 
the forehead, periocular area and nose, and in this case was verified by PCR swab of a 
forehead blister. Herpes zoster is the second clinical manifestation of varicella-zoster 
virus (VZV) and occurs only in individuals who have had primary VZV infection 
(varicella) and with increasing frequency in the elderly as a result of waning of cell-
mediated immunity.8 In immunocompetent individuals, psychological stress and trauma 
have been identified as additional risk factors.12 Our relatively young patient, denied 
experiencing any recent trauma, nor any atypical psychological stress. The most 
serious complications of HZO develop from involvement of the nasociliary branch of the 
trigeminal nerve, which innervates the globe.12 If the eye becomes involved, the ocular 
sequelae can include blepharoconjunctivitis, episcleritis, scleritis, punctate epithelial 
keratitis, dendritic keratitis, anterior stromal keratitis, neurotrophic keratopathy, uveitis 
with varying different degrees of associated ocular damage and visual impairment.  In 
addition to the vision threatening complications of HZO, the most common complication 
of herpes zoster is post herpetic neuralgia (PHN), which can cause chronic and 
debilitating pain and suffering for years and is often refractory to treatment.8,12  
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Current management strategies for acute herpetic stromal keratitis based on the results 
of the Herpes Eye Disease Studies (HEDS) were employed to manage this patient’s 
herpetic corneal disease. These strategies are aimed at inhibiting viral replication with 
oral or topical antiviral medications and broadly inhibiting the damaging immune 
response with topical corticosteroids.11,13,14  
The current standard of care for both necrotizing and non-necrotizing HSV stromal 
keratitis includes topical corticosteroids and topical antivirals.11 In HSV stromal disease, 
a 10 week tapering course of topical corticosteroid (prednisolone) combined with 
topical antiviral cover reduced the persistence and progression of the disease and 
shortened the duration of stromal inflammation.13 Furthermore, no additional benefit 
was observed upon administration of oral acyclovir, compared to placebo, in 
conjunction with topical corticosteroids and topical antivirals.14 The topical antiviral used 
in the HEDS study, trifluridine ophthalmic solution 1%, is unavailable through the  
Australian Pharmaceutical Benefits Scheme (PBS), and an alternative PBS listed 
antiviral, topical acyclovir ointment 3%, was used. In rare cases of topical acyclovir 
resistance, trifluridine ophthalmic solution can be accessed through the Australian 
Therapeutic Goods Administration’s Special Access Scheme. Simultaneous use of the 
topical acyclovir antiviral ointment and topical prednisolone acetate suspension could 
potentially retard the absorption of the steroid suspension. Hence separation of the 
timing of the instillation of antiviral ointment and topical steroid warrants consideration 
and increased dosing of the topical steroid may be required if the stromal inflammation 
fails to respond to treatment. With protracted use of the topical antiviral over 10-14 
days, a toxic epitheliopathy typically arises, which can aid penetration of the topical 
steroid into the stroma as the epithelium is the greatest barrier to steroid penetration. 
Changing the route of administration from topical to oral acyclovir may be considered if 
the toxic epitheliopathy is severe and non-preserved unit dose artificial tears can be 
prescribed improve epithelial health and comfort. 
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HEDS also demonstrated that antiviral therapy with oral acyclovir 400mg twice daily 
significantly reduced the recurrence of stromal HSV keratitis.15 Many clinicians now use 
valacyclovir, 500 mg once daily for prophylaxis due to its equivalent efficacy, greater 
bioavailability and simpler dosing regimen.16 This prophylactic course of oral antiviral 
for herpetic corneal disease is not covered by the PBS and hence the affordability of 
ongoing antiviral prophylaxis is an issue for patients.  
Longer term follow up data from the HEDS study, suggest when the UV index was 
higher (i.e., ≥4), spending 8 or more hours per week outdoors was associated with 
increased risk of ocular HSV recurrence.17 With the average UV Index in Brisbane 
being ≥4 year round, wearing close-fitting wraparound sunglasses and a hat has been 
advised for all outdoor activities.  
 In the case of HZO, the HEDS studies have demonstrated that oral antivirals, 
administered ideally within the first 24-72 hours of onset of the zoster rash for 7 days 
decrease pain, shorten the duration of viral shedding, promote healing of skin lesions 
and decrease the incidence of ocular complications.18 Whilst our patient was 
administrated the oral antivirals at 48 hours, antivirals given after 3 days may still be 
effective in treating HZ.19 There are several antivirals available for herpes zoster 
infection, including acyclovir (800 mg, five times daily), valacyclovir (1000mg, three 
times daily) or famciclovir (500 mg three times daily) which when used for 7 days 
proved to be therapeutically equivalent in regards to resolution of zoster-associated 
pain, PHN, cutaneous healing and treatment safety. Valacyclovir was prescribed in this 
instance due to its higher in bioavailability and less rigorous dosing schedule.19  
Unfortunately oral antivirals do not reliably prevent PHN.18,19 The goal of treating PHN 
is to manage the neuropathic pain, which may require several therapies. Management 
should be guided by patient’s age, co-morbidities, preferences and costs, and involve 
the patient’s general practitioner. First-line therapies, all assessed with randomized 
clinical trials, include GABA analogues (gabapentin and pregabalin), lidocaine patch 
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and tricyclic antidepressants. A recent expert opinion publication recommended GABA 
analogues and topical lidocaine 5% patches as first line PHN treatments, because both 
demonstrated efficacy in treating PHN and are relatively safe.19 The risk of PHN and 
severity of pain increases with age and not all sufferers respond to pharmacological 
interventions.19 Our relatively young patient experienced moderate but short-term PHN 
adequately controlled with pregabalin which is PBS listed for neuropathic pain not 
satisfactorily controlled using other drugs. 
Of the available choices, and in line with current practice patterns,20 the topical steroid 
prednisolone acetate 1% was prescribed for the right ISK with a slow taper over 3 
months due to the chronic/recurrent nature of the disease. Whilst HZO associated ISK 
and iritis have commonly been described as immunologically mediated diseases, there 
is growing evidence that these complications may also be mediated by chronic or 
recurrent zoster infection and a belief amongst the majority of recently surveyed 
corneal specialists that prolonged antiviral therapy could reduce recurrences of HZO 
whilst it is being administered. Currently there is an absence of studies and hence 
treatment guidelines for recurrent or chronic HZO regarding the efficacy of prolonged 
antiviral therapy or the adult zoster vaccine to reduce chronic or recurrent HZO corneal 
disease.20 
Conclusions 
This unusual manifestation of bilateral herpetic ISK in a young immunocompetent 
patient will require ongoing management and review. An important contributor to visual 
loss from corneal herpetic disease is its’ chronic and /or recurrent and neurotrophic 
nature and hence routine ocular surface management strategies have been prescribed.  
Our patient has been advised of his diminished bilateral corneal sensitivity and 
encouraged to present promptly should he notice any change in vision or symptoms 
10 
 
that might suggest reactivations or recurrences, or secondary complications. This will 
afford him the best opportunity for early intervention and minimise further vision loss. 
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Figure Captions 
Figure 1. Right inferior inferior vascularisation due to past chemical burn. The central 
cornea is clear. 
Figure 2. Left vascularised immune stromal keratitis associated with HSV-1 under low 
(2A) and high (2B) magnification at initial presentation and at 10 months post initial 
presentation (2C). 
Figure 3. Right Herpes zoster ophthalmicus rash eruption (3A) and associated immune 
stromal keratitis under low (3B) and high magnification (3C). 
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